Business Wire

Westlake Epoxy Announces Strategic Collaboration With Alpha Recyclage Composites to Advance Composites Recycling

12.6.2025 08:00:00 CEST | Business Wire | Press Release

Share

Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy will collaborate with Alpha Recyclage Composites to support them in scaling up the recycling capacity for carbon fiber composite materials. This collaboration will provide support to Westlake’s composite customers in their development of improved circular options for both production (scrap or off spec composite materials that otherwise become waste) and end-of-life waste. The recovery of the carbon fibers from composite materials for reuse in new or emerging applications aims to establish a more sustainable alternative to traditional disposal methods such as landfilling and incineration.

Alpha Recyclage Composites, a family-owned company based in Toulouse and Castelsarrasin, France, specializes in recycling carbon-fibers-reinforced composites through a patented steam pyrolysis process. This innovative technology preserves the performance qualities of the carbon fibers used in composite materials recovered from applications including aerospace components, automotive parts, and wind turbine blades. With Westlake’s support and to meet growing demand, Alpha Recyclage Composites is expanding its current batch unit to a semi-continuous operation, targeting a capacity of 1,000 metric tons of waste carbon fiber composites recycled per year by 2027.

“We are pleased to collaborate with Alpha Recyclage,” says Brian Powers, Vice President – Westlake Epoxy. “This initiative supports Westlake's broader sustainability goals and aligns with industry’s efforts and our customers’ objectives to reduce waste and promote the reuse of valuable materials through circular solutions.”

By fostering the relationships between Westlake’s composite customers and Alpha Recyclage Composites, Westlake Epoxy aims to connect its customers to Alpha Recyclage’s expanded capacity and in turn support composite customers in their development of new applications that integrate recycled carbon fibers in different forms. The development of new applications utilizing the recovered carbon fibers could pair well with Westlake Epoxy’s EpoVIVE™ portfolio of resin grades with varying sustainable characteristics, like resins that utilize mass balanced renewable raw materials. Westlake Epoxy also plans to leverage this collaboration with Alpha Recyclage to explore and develop solutions for the recovery of organic components from composite materials and how those recovered organics can be applied to further enhance circularity options for the composites value chain.

Laura Pech, CEO of Alpha Recyclage Composites, added: “With over 25 years of experience in tires recycling, including a large-scale steam pyrolysis plant for tires – our family is proud to adapt this process to composite materials. We view Westlake as a strategic collaborator to help us grow this initiative into a more sustainable and profitable business.”

About Westlake

Westlake Corporation (NYSE: WLK) is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe, and North America, we provide building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the company's web site at www.westlake.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250611872753/en/

Contacts

Media contact:

Dr. Oliver Mieden, Head of Communications & Public Affairs – Europe and Asia
Westlake Germany GmbH & Co. KG, Carl-Zeiss-Ring 25, 85737 Ismaning, Germany
Phone: +49 (0)89 96103-282, E-mail: oliver.mieden@westlake.com

Mila Hierner, Global Marketing Communication Manager
Westlake Epoxy Belgium BV, Avenue Jean Monnet 1, 1348 Ottignies
Louvain-la-Neuve, Belgium
Office: +32 10 48 22 50, E-mail: mila.hierner@westlake.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye